Rhumbline Advisers Black Diamond Therapeutics, Inc. Transaction History

Rhumbline Advisers

$105 Billion
Q2 2024

A detailed history of Rhumbline Advisers transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 46,850 shares of BDTX stock, worth $195,364. This represents 0.0% of its overall portfolio holdings.

Number of Shares

46,850

Previous 449 10334.3%

Holding current value

$195,364

Previous $2,000 10800.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	BUY	$4.65 - $7.39 $215,764 - $342,903	46,401 Added 10334.3%	46,850 $218,000
Q2 2023 Aug 08, 2023	BUY	$1.43 - $6.18 $642 - $2,774	449 New	449 $2,000
Q2 2022 Aug 11, 2022	SELL	$1.5 - $3.63 $43,596 - $105,502	-29,064 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$2.66 - $5.61 $4,652 - $9,811	-1,749 Reduced 5.68%	29,064 $81,000
Q4 2021 Feb 10, 2022	SELL	$5.18 - $8.48 $3,004 - $4,918	-580 Reduced 1.85%	30,813 $164,000
Q3 2021 Nov 12, 2021	BUY	$8.46 - $12.42 $9,094 - $13,351	1,075 Added 3.55%	31,393 $266,000
Q2 2021 Aug 05, 2021	BUY	$12.19 - $28.17 $146,426 - $338,378	12,012 Added 65.62%	30,318 $370,000
Q1 2021 May 06, 2021	SELL	$22.23 - $34.75 $24,564 - $38,398	-1,105 Reduced 5.69%	18,306 $444,000
Q4 2020 Feb 10, 2021	BUY	$29.47 - $35.0 $70,492 - $83,720	2,392 Added 14.05%	19,411 $622,000
Q3 2020 Nov 12, 2020	BUY	$26.17 - $43.07 $49,173 - $80,928	1,879 Added 12.41%	17,019 $514,000
Q2 2020 Aug 13, 2020	BUY	$22.3 - $44.8 $68,661 - $137,939	3,079 Added 25.53%	15,140 $638,000
Q1 2020 May 06, 2020	BUY	$18.18 - $39.48 $219,268 - $476,168	12,061 New	12,061 $301,000

Others Institutions Holding BDTX

# of Institutions

100

Shares Held

47.3M

Call Options Held

108K

Put Options Held

24.8K

View Full List

About Black Diamond Therapeutics, Inc.

Ticker BDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,339,500
Market Cap $152M
Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...

More about BDTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Black Diamond Therapeutics, Inc. Transaction History